Under the agreement, Ergomed will be conducting the first clinical trials for one of Hikma’s key oncology (anti-cancer) products in Jordanian hospitals with plans of potential expansion in the Mena region.
Ergomed will manage clinical trials of Hikma treatments in a pilot project in Jordan, and in turn, Hikma will provide Ergomed with an expanded insight into the regional pharmaceutical sector.
Hikma Pharmaceuticals CEO Said Darwazah said their work with Ergomed supports the company’s commitment in medical advancement through the use of clinical trials, especially in the field of oncology.
Hikma Pharmaceuticals is focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in licensed products.